Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study.

Transl Lung Cancer Res

Gastrointestinal Oncology Division, National Cancer Center Hospital, Chuo-ku, Tokyo 1040045, Japan.

Published: June 2015

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483483	PMC
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.03.04	DOI Listing

Publication Analysis

erlotinib bevacizumab

bevacizumab first-line

first-line therapy

therapy patients

patients advanced

advanced non-squamous

non-squamous non-small-cell

non-small-cell lung

lung cancer

cancer harboring

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!